Health Care • Biopharmaceuticals, GLP-1/GIP Cardiometabolic & Oncology • SIC 2834
$1,417.54 ▲ +43.84
(+3.19%)
MKT CAP: $1.34T • VOL: 5.03M
52W L $810 52W H $1,450
RED <GO>
ACCESSION DIFF: 0000059478-25-000067 (2025-02-19)
──► 0000059478-26-000013 (2026-02-12)
Eli Lilly's FY2025 10-K redline reflects sharp structural escalation in manufacturing reliance, compounding liability, and pricing renegotiation exposure tied to tirzepatide (Mounjaro/Zepbound). Disclosures across Item 1A and MD&A signal accelerating CDMO fill-finish bottlenecks, tightening payer formulary concessions, and heightened legal risk surrounding compounding pharmacy patent defense. Accession 0000059478-26-000013 reveals elevated capex absorption risks as external supply constraints intersect with potential GLP-1 margin compression.
HUNK 01 // ITEM 1A // RISK FACTORS — STERILE FILL-FINISH CDMO BOTTLENECKS & PEPTIDE CAPACITY
SEVERITY: CRITICAL [-] PRIOR FILING: FY2024 10-K (Filed 2025-02-19) REMOVED / SUPERSEDED
We rely on third-party manufacturers and our internal network to produce sufficient quantities of commercial products, and temporary disruptions may periodically impact inventory levels.
[+] CURRENT FILING: FY2025 10-K (Filed 2026-02-12) INSERTED DISCLOSURE
Inability of third-party contract development and manufacturing organizations (CDMOs) or our internal facilities to scale sterile fill-finish operations and device assembly to meet sustained demand for incretin products has resulted in supply allocations, regulatory scrutiny, and could impair revenue realization.
FORENSIC TRANSLATION // Management is admitting that outsourced device assembly and sterile injectable capacity cannot keep up with runaway tirzepatide demand, capping near-term revenue upside and exposing Lilly to commercial penalties and market-share leakage to Novo Nordisk.
HUNK 02 // ITEM 1A // RISK FACTORS — COMPOUNDING PHARMACY PROLIFERATION & PATENT LITIGATION
SEVERITY: MEDIUM [-] PRIOR FILING: FY2024 10-K (Filed 2025-02-19) REMOVED / SUPERSEDED
We monitor the unauthorized marketing of counterfeit or compounded versions of our products and initiate legal proceedings when appropriate to protect patient safety.
[+] CURRENT FILING: FY2025 10-K (Filed 2026-02-12) INSERTED DISCLOSURE
Widespread commercial compounding of tirzepatide products under statutory shortage exemptions poses ongoing revenue displacement, intellectual property dilution, and heightened legal costs to enforce exclusivity following the resolution of official shortage designations.
FORENSIC TRANSLATION // Unauthorized compounded GLP-1 sales have established an entrenched parallel market that is directly cannibalizing high-margin US commercial volumes, forcing Lilly into protracted and expensive multi-jurisdiction litigation as official FDA shortage lists normalize.
HUNK 03 // ITEM 7 // MD&A — PBM NET PRICE REALIZATION & GROSS-TO-NET COMPRESSION
SEVERITY: CRITICAL [-] PRIOR FILING: FY2024 10-K (Filed 2025-02-19) REMOVED / SUPERSEDED
U.S. revenue growth was driven by higher realized prices and increased demand across key commercialized cardiometabolic therapies.
[+] CURRENT FILING: FY2025 10-K (Filed 2026-02-12) INSERTED DISCLOSURE
Increased volume adoption in our cardiometabolic portfolio was partially offset by unfavorable gross-to-net price realizations resulting from higher mandatory rebates, commercial access concessions to pharmacy benefit managers (PBMs), and government healthcare program channel mix shifts.
FORENSIC TRANSLATION // Top-line volume acceleration is masking severe rebate expansion. The Big 3 PBMs are capturing larger gross-to-net discounts in exchange for formulary placement, setting the stage for future operating margin compression once volume growth normalizes.